May #47 : The Way We Live Now: Mary Lucey

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Archives » POZ Magazine issues

Table of Contents

A POZ Family Album

POZ 5TH Anniversary Issue: Year One

POZ 5TH Anniversary Issue: Year Two

POZ 5TH Anniversary Issue: Year Three

POZ 5TH Anniversary Issue: Year Four

POZ 5TH Anniversary Issue: Year Five

POZ 5TH Anniversary Issue: Profiles

The Way We Live Now

The Way We Live Now: Andrew Sullivan

The Way We Live Now: Jocelyn Elders

The Way We Live Now: Mary Lucey

The Way We Live Now: Rafael Campo

The Way We Live Now: Mathilde Krim

The Way We Live Now: Mario Cooper

The Way We Live Now: Richard Goldstein

The Way We Live Now: Phill Wilson

The Way We Live Now: Michael Saag

The Way We Live Now: David Ho

The Way We Live Now: Jon Kaiser

The Way We Live Now: Sarah Schulman

The Way We Live Now: Judy Greenspan

The Way We Live Now: Eric Rofes & Dan Savage

The Way We Live Now: Kaiya Montaocean

The Way We Live Now: Ashok Row Kavi

The Way We Live Now: Pat Califia

The Way We Live Now: Asia Russell & Julie Davids

The Way We Live Now: Dennis DeLeon

The Way We Live Now: Jason Farrell

The Way We Live Now: Pernessa Seele

Honeymoon to HAARTache

Monkey Business


When Plagues Return

To the Editor

School Ties

The Bottom Line

Up Close & Personal

Say What

Two Peas in a POZ

In Cold Blood


Rubber Poll

Poster of the Month

Success Has Made a Failure of Us

POZarazzi: The Bod Squad

Saint Sorge


Anecdotal Antidotes

Get Over It

Rubdown Lowdown

The Berlin Stories

T-20, Coming to a Combo Near You

Pill Drill

Suck in Your Gut

Put the Gart Before the Course

Where to Find It

The Skinny on Lipo


The Road to Wellville


Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

email print

May 1999

The Way We Live Now: Mary Lucey

AIDS Policy Analyst

Q: What kind of moment is this in the epidemic for women?

A: Let's look at the Health and Human Services HIV treatment guidelines for a minute, which drive this country and the rest of the world. A Johns Hopkins study came out in late '98 showing that women get sicker at higher CD4 counts and lower viral load counts than men. So several people approached the HHS guidelines board with this information. And I looked at this board to see who was taking care of the home front for the women -- because we're different from men. We metabolize drugs differently, we require different dosages. And there are maybe 50 men, including about 30 PWAs, on that board -- and they have one woman PWA. One woman, all by herself, advocating on behalf of like 100,000 women in the United States. She doesn't even have a treatment background. Women are 27 percent of the U.S. AIDS population now, and we have one woman on the guidelines board? Not OK.

What happens is women's providers use those guidelines, because they're in rural areas or in public health systems, and they have nothing else. So if the guidelines say there's no difference in dosing, those women won't get a fair shake. You've got to ask, Are they intentionally keeping us out, or are they just too damn stupid to figure out how to include us?

Another inequality: A lot of men are using protease-sparing regimens. I'm doing great on one of these regimens, but most women don't even know about them. They don't know that the clinical outcome is similar to protease regimens -- or that the regimen is so much easier to take -- because they're not offered the option. Women come in to their doctors sicker, they let their doctors lead them by the nose, and most of their doctors are not AIDS experts. So treatment is drastically different for women.

You know what else? It's 20 years into the epidemic and we have four treatment studies for women. I have to applaud private industry for finally designing the studies, but they're not stupid. They see that in the near future, 40 percent of their consumers will be women, and those women will say, Did you study our dosage? Whereas, even though we know that toxicity and absorption are drastically different for men and women, the FDA still doesn't require different dosing guidelines by gender. They have geriatric guidelines, pediatric guidelines! But they have nothing for women.

So as far as treatment goes, no, I'm not content at all. As long as women take the same dosages as men, knowing there's a clinical difference, no, I'm not happy. As long as we have four studies in 20 years looking at treatment in women, I'm not happy, because what do we have, 7,000 for men? And as long as women don't know about their options because they're not offered by their paternalistic providers, no, I'm not happy.

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Has a pet helped you deal with your HIV?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.